Consuming a marijuana-based drug may be safe in treating children with severe epilepsy, results of a clinical trial has showed.
Following treatment with cannabidiol -- a non-psychoactive compound found in marijuana -- about one in five children were described as much or very much improved from their baseline, while around half reported none, or a very slight improvement, Xinhua news agency reported.
While the trial was conducted on a small group of children with severe epilepsy, it showed that the drug had a manageable side effect profile, but only showed extensive symptom relief for a brief number of patients.
The trial "involved the sickest children with epilepsy -- children who are having seizures many times per day, who have been recently hospitalized for their epilepsy, and have failed on average about nine anti-epilepsy drugs before," said lead author John Lawson, paediatric neurologist at Sydney's Children's Hospital.
"The main aim of the study was about safety. We found that there were a few safety concerns but overall those safety issues were very manageable and the drug overall was very safe for the majority," he added.
The study was published in the Medical Journal of Australia.
Although legally cannabis must be prescribed by a doctor, recent reports of cannabis derivatives being successful in treating children with epilepsy have led to a number of parents of sick children sourcing their own medical marijuana.
While the study's authors said the results were significant, they stressed that the purpose of this study was about safety not efficacy.
The US Food and Drug Administration had recently approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy -- Lennox-Gastaut syndrome and Dravet syndrome -- in patients two years of age and older.
--IANS
asj/rt/mag/sed
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
